Intelligent biopharma

Forging the links across the value chain

The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies. Among companies that adopt AI technology, 70 percent will obtain AI capabilities through cloud-based enterprise software, and 65 percent will create AI applications using cloud-based development services. In order to keep up with the changing competitive landscape and customer expectations, biopharma companies will need to accelerate their use of AI-enabled services.

Biopharma organizations have started using scaled versions of AI over the last 1-2 years in some areas. While still at an early stage, progress is being made throughout the biopharma value chain, from research and discovery, through clinical development and trials, manufacturing, establishing the supply chain and commercial launch, to post-launch surveillance and customer/patient engagement. The rapid growth in AI across the value chain is being driven by access to vast and growing quantities of data, increases in computing power to analyse the data, improved algorithms and a sharp reduction in the costs of computing.

Based on our research, the four applications that are expected to drive most of the AI market in biopharma between 2018 and 2025 are: drug discovery, precision medicine, medical imaging & diagnostics and research.

Intelligent biopharma

Selected Deloitte engagements

Over the next months, we will explore each of the above areas, focusing on how AI is accelerating progress in each of the four area-specific domains and how organizations can adopt and scale AI to create differentiation in customer experience and accelerate building strategic competitive advantage.

Did you find this useful?